echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Feed Industry News > No serious adverse reactions of Tamiflu in China

    No serious adverse reactions of Tamiflu in China

    • Last Update: 2008-11-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Introduction: the State Administration of supervision has reported the use of Tamiflu (reporter Guo Ying) a few days ago, there were media reports that the use of Tamiflu by foreign people led to serious adverse reactions Yesterday, the State Food and Drug Administration issued a circular on safety and rational use of Tamiflu, pointing out that no serious adverse reactions have been found in China According to the report, as of November 5 this year, the national ADR case report database has included 52 cases of Tamiflu and 57 cases of adverse reactions, mainly involving the gastrointestinal system, showing nausea, dizziness and other symptoms At present, no serious adverse reactions have been reported According to Xinhua news agency, the Ministry of agriculture received a report from the Hubei provincial headquarters for the prevention and control of highly pathogenic avian influenza yesterday The H5N1 subtype highly pathogenic avian influenza epidemic occurred in Xiaonan District, Xiaogan City, Hubei Province After the measures of blocking, killing, disinfecting and emergency immunization of birds in the threatened area were taken, the epidemic was put out After 21 days of testing, no new infectious source has occurred, which is in line with the provisions of the state on lifting the blockade of the epidemic area The blockade was lifted on December 7 Clinical trials of vaccines in China are divided into four categories Report from our newspaper (reporter Guo Ying) yesterday, Yin Hongzhang, director of the biological products Department of the registration department of the State Food and drug administration, introduced the research progress of human avian influenza vaccine in China He said that the Chinese pandemic influenza vaccine that is about to enter the phase I clinical trial is not a phase I clinical trial in the ordinary sense, but a dosage form test for the unpredictable and accurate target immune virus The pandemic influenza vaccine, which is about to undergo clinical trials, will test immunogenicity at four doses in 100 people.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.